Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
cardiovascular disease
Biotech
UPDATED: Kardigan buttons up $400M upsized IPO for phase 3 push
Kardigan’s IPO haul came in 14% above expectations, grossing $400 million after the biotech upsized the offering and hit the top end of its range.
Nick Paul Taylor
,
Will Maddox
Jun 18, 2026 7:28am
J&J’s Impella pumps miss the mark in 2 major PCI studies
Mar 30, 2026 3:20pm
Merck dives into data showing PCSK9 pill easily outswims rivals
Mar 30, 2026 11:45am
Philips AI cath lab copilot nets FDA clearance
Mar 26, 2026 10:45am
Medtronic, Biotronik make strides in conduction system pacing
Mar 24, 2026 11:20am
XCath completes remote-controlled robotic stroke procedure
Mar 19, 2026 8:00am
